Tag:

Novartis

Latest Headlines

Latest Headlines

Post-Novartis deal, GSK's top dog in vaccines, consumer health. Now what?

GlaxoSmithKline and Novartis have finally closed the multibillion-dollar asset swap that's sending GSK's oncology portfolio to Switzerland in exchange for most of the latter's vaccines unit. Now, all eyes will be on the British pharma giant, who industry watchers agree has more to prove after exiting the fast-growing cancer field.

GSK deal's done. Now, Novartis has to deliver on cancer-growth pledge

Novartis has been rubbing its hands together in anticipation of taking over GlaxoSmithKline's cancer portfolio. Now it can. The two drug giants wrapped up their big sale-and-swap, putting Novartis in charge of GSK oncology meds, from Arzerra to Votrient.

Pfizer, Novartis: CDC's MenB nod is too narrow

Pfizer and Novartis have snagged a nod from the CDC's Advisory Committee on Immunization Practices for their recently approved meningitis B vaccines. There's just one problem: It doesn't cover nearly as large a population as the pharma giants would like.

Novartis looks to squelch neuro worries over its would-be cardio blockbuster

Novartis, at work on a cardio drug widely expected to bring in billions of dollars once approved, is working to tamp down concerns that the oral treatment could increase the risk of Alzheimer's disease, adding measures of brain function to an ongoing trial.

Japan unit of Novartis sees most sales suspended 15 days over ADR failures

Japan's health ministry on Friday told the local unit of Swiss-based Novartis to suspend most sales operations for just over two weeks.

Pfizer, Novartis get MenB ACIP nod--but not the one they're really after

Pfizer and Novartis officially have a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. Problem is, it doesn't cover nearly as large a population as the pharma giants would like.

Deal-weighing Pharmacyclics could draw $18B from J&J, Novartis: Bloomberg

So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going.

British doctors lobby NHS to use cheap Avastin over Lucentis in AMD

Here's a new threat to Lucentis, the eye drug from Roche and Novartis. British doctors are calling for the National Health Service to routinely use Roche's cancer med Avastin to treat patients with wet age-related macular degeneration, rather than the much costlier Lucentis.

Novartis bags a surprise approval for the blood cancer-treating panobinostat

Going against the advice of its independent experts, the FDA approved Novartis' new blood cancer drug for patients with particularly deadly forms of multiple myeloma, looking past some serious safety issues and concerns about the drug's supporting data.

Novartis leads a $28M round for rare disease biotech Merganser

Pennsylvania's Merganser Biotech raised a $28 million A round with the help of Novartis Venture Fund, paying the company's way as it homes in on iron-related diseases.